Histopathologic spectrum of morphea: a single-center retrospective study
https://doi.org/10.4081/dr.2024.9915
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Background. Morphea is a rare autoimmune disease that often affects the skin and subcutaneous tissue. Objective. The aim of our study is to reveal the relationship between demographic characteristics of the patients, location of the lesions, clinical subtype of morphea and histopathological findings. Methods. We studied 78 patients diagnosed with morphea between 2016 and 2022 at the Department of Pathology, Prof. Dr. Cemil Taşcıoğlu City Hospital. 72 patients were included in the study. Hematoxylin and Eosin stain slides of cases were retrieved from the pathology archive and were evaluated by two pathologists under blinded conditions. Flattening of rete ridges, location of inflammatory infiltrate, grade of inflammatory infiltrate, presence of plasma cells, presence of eosinophils, homogenization of dermal collagen, decrease of skin appendages, basal pigmentation and melanin incontinence were evaluated. Statistical analyses were performed using SPSSv.20. Results. The most common clinical presentation was plaque type(87.5%) and histopathological findings were homogenization of dermal collagen(100%) and decrease of skin appendages (98.7%). Flattening of the rete ridges was observed in 46.2% of the patients. Severity of the inflammatory infiltrate was found to be higher in these patients(p=0.028). Basal pigmentation was observed in 59% of the patients. Line sign was more common in lower extremity lesions among all localizations (p=0.015). Conclusions. The histopathologic features of morphea are variable and confusing. Particularly, in cases with collagen homogenization, morphea should be considered in differential diagnosis with clinical correlation. In addition, the ‘line’ sign could be helpful for identifying lesions located in the lower extremities.
Hawk A, English JC 3rd. Localized and systemic scleroderma. Semin Cutan Med Surg. 2001; 20:27-37. DOI: https://doi.org/10.1053/sder.2001.23093
Walker D, Susa JS, Currimbhoy S, Jacobe H. Histopathological changes in morphea and their clinical correlates: results from the Morphea in Adults and Children Cohort V. J Am Acad Dermatol. 2017; 76:1124-1130. DOI: https://doi.org/10.1016/j.jaad.2016.12.020
Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol 2008; 59:385-396. DOI: https://doi.org/10.1016/j.jaad.2008.05.005
Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 2006; 45:614-620. DOI: https://doi.org/10.1093/rheumatology/kei251
Fett N, Werth VP, Update on morphea: Part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011; 64:217-228. DOI: https://doi.org/10.1016/j.jaad.2010.05.045
Hong JH, Kim JE, Ko JY, Ro YS. A clinicopathologic study of morphea in Korean patients. J Cutan Pathol. 2015; 42:929-936. DOI: https://doi.org/10.1111/cup.12528
Chiu YE, Abban CY, Konicke K, Segura A, Sokumbi O. Histopathologic Spectrum of Morphea. The Am J Dermatopathology. 2021; 43:1-8. DOI: https://doi.org/10.1097/DAD.0000000000001662
Onajin O, Wieland CN, Peters MS, Lohse CM, Lehman JS.Clinicopathologic and immunophenotypic features of eosinophilic fasciitis and morphea profunda: a comparative study of 27 cases. J Am Acad Dermatol. 2018; 78:121-128. DOI: https://doi.org/10.1016/j.jaad.2017.06.148
Succaria F, Kurban M, Kibbi AG, Abbas O. Clinicopathological study of 81 cases of localized and systemic scleroderma. J Eur Acad Dermatol Venereol. 2013; 27:191-196. DOI: https://doi.org/10.1111/j.1468-3083.2012.04581.x
Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, et al. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatol Venereol. 2017; 31:1401-1424. DOI: https://doi.org/10.1111/jdv.14458
Lis-Swiety A, Skrzypek-Salamon A, Ranosz-Janicka I, Brzezinska-Wcislo L. Localized scleroderma: clinical and epidemiological features with emphasis on adulthood- versus childhood-onset disease differences. J Eur Acad Dermatol Venereol. 2017; 31:1595-1603. DOI: https://doi.org/10.1111/jdv.14197
Nehir Parlak, Bengü Nisa Akay, Hatice Erdi Şanlı, Aynur Akyol. The clinical features, laboratory findings, treatment and follow-up results of patients with morphea. Türkderm 2013; 47: 209-213. DOI: https://doi.org/10.4274/turkderm.05657
Toledano C, Rabhi S, Kettaneh A, et al: Localized scleroderma: a series of 52 patients. Curr Opin Rheumatol 2009; 20:331-336. DOI: https://doi.org/10.1016/j.ejim.2008.07.011
Prasad S, Zhu JL, Schollaert-Fitch K, Torok KS, Jacobe HT. An Evaluation of the Performance of Current Morphea Subtype Classifications. JAMA Dermatol. 2021 Apr 1;157(4):1-8. DOI: https://doi.org/10.1001/jamadermatol.2020.5809
Kim J, Chung KB, Lee YI, Kim J, Lee JH. Clinical characteristics and histopathologic changes of morphea: A single-center, retrospective study of 137 patients. J Am Acad Dermatol. 2021; 85:105-113. DOI: https://doi.org/10.1016/j.jaad.2020.11.006
Yang S, Draznin M, Fung MA. The "Line Sign" Is a Rapid and Efficient Diagnostic "Test" for Morphea: Clinicopathological Study of 73 Cases. Am J Dermatopathol. 2018; 40:873-878. DOI: https://doi.org/10.1097/DAD.0000000000001177
Walters R, Pulitzer M, Kamino H. Elastic fiber pattern in scleroderma/morphea. J Cutan Pathol. 2009; 36:952–957. DOI: https://doi.org/10.1111/j.1600-0560.2009.01201.x
Ghoreishi M, Vera Kellet C, Dutz JP. Type 1 IFN-induced protein MxA and plasmacytoid dendritic cells in lesions of morphea. Exp Dermatol. 2012; 21:417–419. DOI: https://doi.org/10.1111/j.1600-0625.2012.01475.x
Grewal I, Khan O, Davis W. Squamous cell carcinoma and eosinophilia in a long-term course of pansclerotic morphea. BMJ Case Rep. 2014 Oct 13;2014: bcr2014205737. DOI: https://doi.org/10.1136/bcr-2014-205737
Wollina U, Buslau M, Heinig B, Petrov I, Unger E, Kyriakopoulou E, Koch A et Al. Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma. Int J Low Extrem Wounds. 2007; 6:291-298. DOI: https://doi.org/10.1177/1534734607308731
Kunzler E, Florez-Pollack S, Teske N, O'Brien J, Prasad S, Jacobe H. Linear morphea: Clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort. J Am Acad Dermatol. 2019; 80:1664-1670 DOI: https://doi.org/10.1016/j.jaad.2019.01.050
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
